Involvement of the c‐erbB‐2 oncogene product in the egf‐induced cell motility of sk‐ov‐3 ovarian cancer cells

The epidermal growth factor (EGF) induces the rapid formation of dendritic processes and the dissociation of SK‐OV‐3 ovarian cancer cells. The SK‐OV‐3 cell line is characterized by over‐expression of the c‐erbB‐2 oncogene product (p185c‐erbB‐2). To investigate the role of p185c‐erbB‐2 in cell motility, a c‐erbB‐2‐specific single‐chain antibody was expressed in SK‐OV‐3 cells using a retroviral expression vector. Eight individual clones expressing the single chain antibody were isolated. These clones have prominent retention of the cell‐surface p185c‐erbB‐2. The EGF‐induced morphologic changes and cell motility of the single‐chain‐antibody‐expressing clones were strongly inhibited, as observed in cell dissociation and in transmigration experiments. However, the suppression of p185c‐erbB‐2 does not inhibit the motility signal elicited by 12‐O‐tetradecanoyl‐phorbol‐13‐acetate. These data indicate that the c‐erbB‐2 oncogene product is essential to mediate the motility signal of EGF to SK‐OV‐3 ovarian cancer cells. The enhancement of tumor‐cell motility may be partially responsible for the unfavorable prognosis of ovarian cancer with over‐expression of c‐erbB‐2. Int. J. Cancer 83:409–414, 1999. © 1999 Wiley‐Liss, Inc.

[1]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[2]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[4]  C. Macleod,et al.  Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. , 1990, The Journal of clinical investigation.

[5]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. A. Carraway,et al.  Association of p185neu with microfilaments via a large glycoprotein complex in mammary carcinoma microvilli. Evidence for a microfilament-associated signal transduction particle. , 1993, The Journal of biological chemistry.

[7]  G. Nolan,et al.  Production of high-titer helper-free retroviruses by transient transfection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  K.,et al.  The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. , 1994, The Journal of biological chemistry.

[9]  H. Roels,et al.  Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast , 1994, Histopathology.

[10]  W. Grizzle,et al.  Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. , 1994, Journal of the National Cancer Institute.

[11]  J. Vandekerckhove,et al.  A 50 kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of Neu/HER-2, in human SK-BR-3 mammary cancer cells. , 1994, Journal of cell science.

[12]  A. Schauer,et al.  Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. , 1994, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  T. Sasaki,et al.  Involvement of Rho p21 small GTP-binding protein and its regulator in the HGF-induced cell motility. , 1994, Oncogene.

[14]  Y. Yarden,et al.  Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2 , 1995, Molecular and cellular biology.

[15]  M. Dietel,et al.  c‐erbB‐2 anti‐sense phosphorothioate oligodeoxynucleotides inhibit growth and serum‐induced cell spreading of p185c‐erbB‐2‐overexpressing ovarian carcinoma cells , 1995, International journal of cancer.

[16]  N. Hynes,et al.  Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling , 1995, Molecular and cellular biology.

[17]  K. Dameron,et al.  Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity , 1997, Oncogene.

[18]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[19]  L. Hudson,et al.  Epidermal growth factor (EGF)‐ and scatter factor/hepatocyte growth factor (SF/HGF)‐mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)‐9 , 1998, Journal of cellular physiology.

[20]  M. Sliwkowski,et al.  Binding specificities and affinities of egf domains for ErbB receptors , 1999, FEBS letters.